Cystic fibrosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
==Medical Therapy== | ==Medical Therapy== | ||
* Inhaled osmotic agent/ Hypertonic saline: Increase the airway fluid layer <ref name="pmid19393104">{{cite journal |vauthors=Ratjen FA |title=Cystic fibrosis: pathogenesis and future treatment strategies |journal=Respir Care |volume=54 |issue=5 |pages=595–605 |year=2009 |pmid=19393104 |doi= |url=}}</ref> | * Inhaled osmotic agent/ Hypertonic saline: Increase the airway fluid layer <ref name="pmid19393104">{{cite journal |vauthors=Ratjen FA |title=Cystic fibrosis: pathogenesis and future treatment strategies |journal=Respir Care |volume=54 |issue=5 |pages=595–605 |year=2009 |pmid=19393104 |doi= |url=}}</ref> | ||
* Dornase alfa [recombinant human deoxyribo-nuclease (DNase)]: Cleave | * Dornase alfa [recombinant human deoxyribo-nuclease (DNase)]: Cleave the extracellular DNA and aid airway clearance (DNA significantly increases the viscosity of the sputum) <ref name="pmid27347364">{{cite journal |vauthors=Edmondson C, Davies JC |title=Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications |journal=Ther Adv Chronic Dis |volume=7 |issue=3 |pages=170–83 |year=2016 |pmid=27347364 |pmc=4907071 |doi=10.1177/2040622316641352 |url=}}</ref> | ||
{| class="wikitable" | |||
! colspan="3" |Summary table of medical treatment in patients with Cystic fibrosis | |||
|- | |||
|'''Category''' | |||
|'''Approaches''' | |||
|'''Current status''' | |||
|- | |||
| rowspan="2" |Mucolytic agents | |||
|Dornase alfa | |||
| | |||
|- | |||
|N-acetyl-L-cysteine | |||
| | |||
|- | |||
| rowspan="2" |Airway surface rehydration | |||
|Hypertonic saline | |||
| | |||
|- | |||
| | |||
| | |||
|- | |||
|Anti-infective agents | |||
| | |||
| | |||
|- | |||
|Inflammation | |||
| | |||
| | |||
|- | |||
|CFTR protein defect | |||
| | |||
| | |||
|} | |||
==References== | ==References== | ||
Revision as of 21:31, 13 February 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
|
Cystic fibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cystic fibrosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Cystic fibrosis medical therapy |
|
Risk calculators and risk factors for Cystic fibrosis medical therapy |
Overview
Medical Therapy
- Inhaled osmotic agent/ Hypertonic saline: Increase the airway fluid layer [1]
- Dornase alfa [recombinant human deoxyribo-nuclease (DNase)]: Cleave the extracellular DNA and aid airway clearance (DNA significantly increases the viscosity of the sputum) [2]
| Summary table of medical treatment in patients with Cystic fibrosis | ||
|---|---|---|
| Category | Approaches | Current status |
| Mucolytic agents | Dornase alfa | |
| N-acetyl-L-cysteine | ||
| Airway surface rehydration | Hypertonic saline | |
| Anti-infective agents | ||
| Inflammation | ||
| CFTR protein defect | ||
References
- ↑ Ratjen FA (2009). "Cystic fibrosis: pathogenesis and future treatment strategies". Respir Care. 54 (5): 595–605. PMID 19393104.
- ↑ Edmondson C, Davies JC (2016). "Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications". Ther Adv Chronic Dis. 7 (3): 170–83. doi:10.1177/2040622316641352. PMC 4907071. PMID 27347364.